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Females with BRCA1/2 mutations have a 40% to 60% lifetime
risk of developing breast cancer and a 16% to 40% risk of devel-
oping ovarian cancer (Friedman et al, 1995; Levy-Lahad et al,
1997). The incomplete penetrance of the BRCA1/2 gene muta-
tions suggests that other factors, genetic and non-genetic, deter-
mine the phenotypic expression of mutant BRCA1/2 alleles.
Candidate ‘modifier genes’ to consider include genes with a
known relevance to breast tumorigenesis (e.g., p53), genes which
physically interact with BRCA1 or BRCA2 (e.g., RAD51), or
those that have an in-vitro effect on the proliferation rate of breast
epithelial cells (e.g., estrogen receptor, vitamin D receptor).
In Ashkenazi Jews three predominant founder mutations were
described (185delAG and 5382insC in BRCA1 and 6174delT in
BRCA2) (Friedman et al, 1995; Modan et al, 1996; Neuhausen
et al, 1996; Tonin et al, 1996). In this population, one could
consider as putative modifier genes, genes that display a high
carrier state and are known to be associated with an increased risk
for cancer. The recently described I1307K missense mutation in
the APC gene, seems to fit into this category. This missense muta-
tion has been detected in 28% of Jewish Ashkenazi individuals
with familial colorectal cancer, and in 6–7% of the general Jewish
Ashkenazi population (Laken et al, 1997; Woodage et al, 1998).
The apparent mechanism underlying cancer predisposition is the
creation of a homopolymer tract (A8), resulting in tissue-specific
genomic instability, prone to acquiring somatic mutation (Laken 
et al, 1997). Several lines of evidence suggest that the APC gene
might participate in breast cancer tumorigenesis. Loss of hetero-
zygosity involving the APC gene has been reported in sporadic
breast tumours (Thompson et al, 1993; Kashiwaba et al, 1994).
Woodage and coworkers (1998) reported that I1307K mutation
carriers are more likely to have a first degree relative with breast
cancer. Redston and coworkers (1998) have affirmed that cancer
risk conferred by mutant BRCA1/2 alleles is increased by the
presence of the I1307K APC polymorphism.
To better delineate an association between the I1307K mutation
and breast/ovarian cancer we determined the prevalence of this
mutation in Jewish patients with inherited and sporadic breast
and/or ovarian cancer.
MATERIAL AND METHODS
Patients and controls
Patients – 366 self-referred or physician-referred patients with
either breast and/or ovarian cancer visiting the Oncogenetics
services at Sheba and Rambam Medical Centers and 159 un-
selected patients with breast cancer seen at Sheba and Rambam
Oncology Clinic during 1997 and 1998. All patients were system-
atically screened for the three predominant BRCA1 and BRCA2
mutations and for the I1307K APC mutation.
Asymptomatic – carriers 53 family members of mutation
carriers or individuals referred because of a family history of
breast/ovarian cancer.
Controls – 418 healthy Ashkenazi individuals who presented
for genetic testing of common recessive diseases. These were
systematically screened for the I1307K APC mutation only.
Data including demographics, histopathological information,
treatment and outcome variables were collected and entered into a
computerized database. All participants signed an informed
consent form approved by the Institutional Review Board (IRB)
and were genotyped for the three predominant founder mutations
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for I1307K APC mutation.
Genotyping
All genotyping was performed on DNA extracted from
lymphocytes.
The 185delAG, 5382insC (BRCA1) and 6174delT (BRCA2)
were detected by PCR amplification with specific primers that
produce a modified restriction enzyme digest made to distinguish
the wild-type allele from the mutant allele, as previously described
(Abeliovich et al, 1997; Rohlfs et al, 1997). The I1307K mutations
(APC) was detected using specific primers that produce a modified
restriction enzyme digest made to distinguish the wild-type allele
from the mutant allele (unpublished data). Alternatively, the APC
I1307K mutation was detected by DGGE and direct sequencing as
previously described (Patael et al, 1999).
Statistical analysis
The c2 (Pearson and Fisher exact) tests were used for comparisons
between groups. Proportions and 95% confidence intervals were
calculated. Odd ratios and 95% confidence intervals were used to
evaluate the prevalence of the APC I1307K mutation in BRCA1/2
carriers and non-carriers whether patients or controls.
RESULTS
Characteristics (tables 1.2)
Patients – 525 patients (mean age 50.9 ± 12.27; range 26–86): 471
with breast cancer (including 16 with both breast and ovarian
cancer); of whom 136 were diagnosed prior to age 42 years and
335 diagnosed after that age; and 54 with ovarian cancer only. Of
these 143 were BRCA1/2 mutation carriers (mean age of onset 
44 ± 9.97; range 28–79); 114 with breast cancer (including 14 with
both breast and ovarian cancer); of whom 55 were diagnosed prior
to age 42 years and 59 diagnosed after that age; and 29 with
ovarian cancer only.
Asymptomatic BRCA1/2 carriers – 53 women (mean age
45.8  ± 11.24; range 27–79).
Control – 418 Ashkenazi individuals.
No statistically significant mean age differences were found
between symptomatic and asymptomatic BRCA1/2 carriers and
between these and non-BRCA1/2 carrier patients.
Distribution of the I1307K APC mutation
Overall 57 (6%) I1307K APC mutation carriers were identified.
The I1307K mutation was equally prevalent among patients with
either sporadic (17/382; 4.6%) or inherited (10/143; 7%) breast
and/or ovarian cancer (OR = 6.27, 95% CI = 0.7–57.7) and among
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Table 1 Distribution of the I1307K allele among patients and healthy participants
Groups Subgroups I1307K Total % 95% CI
carriers
Total 57 996 5.7 4.40–7.40
Healthy controls 23 418 5.5 3.60–8.26
Sporadic cases
Late onset breast cancera 15 276 5.4 3.18–8.99
Early onset breast cancer 1 81 1.2 0.06–7.64
Ovarian cancer 1 25 4 0.21–22.32
All 17 382 4.6 2.70–7.17
BRCA1/2 carriers
Late onset breast cancerb 5 59 8.5 3.16–19.42
Early onset breast cancerc 4 55 7.3 2.36–18.43
OC 1 29 2.8 0.18–19.63
Asymptomatic 7 53 13.2 5.91–25.95
All 17 196 8.7 5.29–13.75
aIncludes 2 patients with both breast and ovarian cancer. bIncludes 10 patients with both breast and ovarian cancer. cIncludes 4 patients with both breast and
ovarian cancer.
Table 2 Prevalence of the I1307K allele among breast and/or ovarian cancer patients and healthy controls with/without BRCA1/2 mutations.
Groups Total BRCA1/2 carriers Non-BRCA1/2 carriers
Total I1307K I1307K Total I1307K I1307K
carriers non-carriers carriers non-carriers
No. % No. % No. % No. % c2 p OR 95% CI
All patients 525 143 10 7 133 93 382 17 4.4 365 95.6 1.07 0.2 1.5 0.7–3.4
Breast cancer patients 471 114 9 7.9 105 92.1 357 16 4.5 341 95.5 2 0.122 1.8 0.8–4.2
Early onset breast cancer 136 55 4 7.3 51 92.7 81 1 1.2 80 98.8 3.4 0.086 6.275 0.7–57.7
Late onset breast cancer 335 59 5 8.5 54 92.5 276 15 5.4 261 94.6 0.8 0.265 1.6 0.6–4.6
Ovarian cancer patients 54 29 1 2.8 28 98.2 25 1 4 24 96 0.01 0.72 0.86 0.02–33.5
Healthy participants 471 53 7 13.2 46 76.8 418 23 5.5 395 94.5 4.68 0.04 2.6 1.1–6.4
Total 996 196 17 8.7 179 91.3 800 40 5 760 95 3.615 0.046 1.7 1–3.1patients with breast cancer only (25/471; 5.3%) whether inherited
(9/114; 7.9%) or sporadic (16/357; 4.9%) (OR = 1.6, 95%
CI = 0.6–4.6).
The I1307K APC mutation was equally distributed among
asymptomatic (7/53; 13.2%) and cancer manifesting BRCA1/2
carriers (10/143; 7%) (P = 0.14; OR = 2, 95% CI = 0.7–5.6). The
I1307K APC mutation was equally distributed among BRCA1/2
carriers diagnosed with breast cancer prior to (4/55; 7.3%) and
after (5/59; 8.5%) age 42 years (P = 0.545; OR = 0.8, 95%
CI = 0.2–3.33). Among women with sporadic breast cancer the
prevalence of the I1307K APC mutation was higher, although not
statistically different, among those diagnosed after 42 years
(15/276; 5.4%) than before (1/81; 1.2%) (P = 0.09; OR = 0.22,
95% CI = 0.03–1.7).
The overall distribution of I1307K APC mutation among
BRCA1/2 carriers (17/196; 8.7%) was found to be significantly
elevated compared to that observed among non-BRCA1/2 carriers
(40/800; 5%) (P = 0.046; OR = 1.7, 95% CI = 1–3.1). The frequency
of the I1307K allele was significantly higher among asymptomatic
BRCA1/2 carriers (7/53; 13.2%) than among healthy controls
(23/418; 5%) (P = 0.04; OR = 2.6, 95% CI = 1.1–6.4).
DISCUSSION
Previous studies suggest that the APC I1307K missense mutation
may act as a low penetrance gene/modifier both for sporadic breast
cancer and breast cancer in BRCA1/2 mutation carriers (Redston
et al, 1998; Woodage et al, 1998). In this study, we show that the
I1307K polymorphism occurs at similar rates in the general
Ashkenazi population and in women with sporadic breast (and/or
ovarian) cancer. Yet among BRCA1/2 mutation carriers a higher
frequency of I1307K mutation carriers was observed. The majority
of patients with sporadic breast cancer patients who carried the
I1307K APC mutation (15/16) had their breast cancer diagnosed
after 42 years of age. No trend for ‘early onset breast cancer’ (< 42
years of age) was observed among double heterozygotes for both
the APC I1307K polymorphism and a BRCA1/2 mutation. Taken
together, these results do not support previously reported data indi-
cating that this specific mutation, or rather polymorphism, confers
a modest increased risk to developing breast cancer in Ashkenazi
women (Redston et al, 1998; Woodage et al, 1998). Intriguingly,
the rate of I1307K mutation in BRCA1/2 germline mutation
carriers, was significantly higher than that observed in non-
BRCA1/2 carriers with the asymptomatic BRCA1/2 mutation
carriers having the highest rate of APC polymorphism. This obser-
vation seems to counteract the prediction (Redston et al, 1998;
Woodage et al, 1998) that the effect of these two germline muta-
tions would be additive, as anticipated from cancer susceptibility
genes. A significantly higher rate of APC mutation carriers with
sporadic breast cancer were indeed diagnosed after rather than
before the age of 42 years, showing again that the APC
polymorphism does not predispose to breast cancer.
Altogether, our results seem to weaken the notion that the
I1307K APC gene polymorphism may act as a low penetrance
gene/modifier in either sporadic or hereditary breast cancer. The
high prevalence of APC mutation carriers among BRCA1/2
carriers does not seem to impinge upon morbidity even though
some possibility of survivor bias should be taken into considera-
tion. A plausible explanation is that the I1307K and BRCA1/2
mutated alleles are genetically connected because of Jewish
ancestry and are not related with cancer risk.
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